Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
Completed · Phase 2
Conditions studied: Prostatic Neoplasms
In brief
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Key facts
- Study ID
- NCT00313781
- Run by
- Pfizer
- People needed
- 204
- Starts
- 2006-05-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2013-04-11
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of metastatic, progressive hormone refractory prostate cancer
- Adequate bone marrow, liver and kidney function
You may not qualify if…
- Previous treatment with chemotherapy
Where it is running
- Pfizer Investigational Site — Los Angeles, California, United States
- Pfizer Investigational Site — New York, New York, United States
- Pfizer Investigational Site — Cleveland, Ohio, United States
- Pfizer Investigational Site — Cleveland, Ohio, United States
- Pfizer Investigational Site — Orange, Ohio, United States
- Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
- Pfizer Investigational Site — Montreal, Quebec, Canada
- Pfizer Investigational Site — Montreal, Quebec, Canada
- Pfizer Investigational Site — Berlin, Germany
- Pfizer Investigational Site — München, Germany
- Pfizer Investigational Site — A Coruña, A Coruña, Spain
- Pfizer Investigational Site — Barcelona, Barcelona, Spain
- Pfizer Investigational Site — L'Hospitalet de Llobregat, Barcelona, Spain
- Pfizer Investigational Site — Sankt Gallen, Switzerland
- Pfizer Investigational Site — Sutton, Surrey, United Kingdom
- Pfizer Investigational Site — Glasgow, United Kingdom
- Pfizer Investigational Site — Glasgow, United Kingdom
- Pfizer Investigational Site — Guildford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.